The Journal of allergy and clinical immunology
-
J. Allergy Clin. Immunol. · Dec 2011
Short ragweed pollen triggers allergic inflammation through Toll-like receptor 4-dependent thymic stromal lymphopoietin/OX40 ligand/OX40 signaling pathways.
Allergic diseases affect a large population. Pollen, an ubiquitous allergen, is the trigger of seasonal rhinitis, conjunctivitis, and asthma, as well as an exacerbating factor of atopic dermatitis. However, the underlying mechanism by which pollen induces thymic stromal lymphopoietin (TSLP)-triggered allergic inflammation through epithelial innate immunity is largely unknown. ⋯ For the first time, we have shown that SRW pollen, acting as a functional TLR4 agonist, initiates TLR4-dependent TSLP/OX40L/OX40 signaling, which triggers T(H)2-dominant allergic inflammation. These findings shed light on the understanding of mucosal epithelial innate immunity and create new therapeutic targets to cure allergic diseases.
-
J. Allergy Clin. Immunol. · Nov 2011
The association of obesity and asthma severity and control in children.
The association between obesity and asthma severity and control in children is not well understood. ⋯ Our findings suggest that childhood obesity is associated with an increased risk of worse asthma control and exacerbations.
-
J. Allergy Clin. Immunol. · Sep 2011
Review Case ReportsEvaluation of the child with recurrent wheezing.
-
J. Allergy Clin. Immunol. · Sep 2011
Randomized Controlled Trial Multicenter StudyA randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria.
Proof-of-concept studies with omalizumab in patients with chronic idiopathic urticaria (CIU) have shown significant decreases in mean urticaria activity scores (UASs). ⋯ This study demonstrated that a fixed dose of 300 or 600 mg of omalizumab provides rapid and effective treatment of CIU in patients who are symptomatic despite treatment with H(1)-antihistamines.